These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Efficacy and safety of deferoxamine, deferasirox and deferiprone triple iron chelator combination therapy for transfusion-dependent β-thalassaemia with very high iron overload: a protocol for randomised controlled clinical trial. Premawardhena A, Perera C, Wijethilaka MN, Wanasinghe SK, Rajakaruna RHMG, Samarasinghe RANKK, Williams S, Mettananda S. BMJ Open; 2024 Feb 08; 14(2):e077342. PubMed ID: 38331857 [Abstract] [Full Text] [Related]
9. Deferasirox for managing iron overload in people with thalassaemia. Meerpohl JJ, Antes G, Rücker G, Fleeman N, Motschall E, Niemeyer CM, Bassler D. Cochrane Database Syst Rev; 2012 Feb 15; (2):CD007476. PubMed ID: 22336831 [Abstract] [Full Text] [Related]
13. Therapeutic efficacy of different iron chelators in Egyptian children with Beta Thalassemia with iron overload. Hagag AA, Hamam MA, Taha OA, Hazaa SM. Infect Disord Drug Targets; 2015 Apr 15; 15(2):98-105. PubMed ID: 26205801 [Abstract] [Full Text] [Related]
14. Differential effects of iron chelators on iron burden and long-term morbidity and mortality outcomes in a large cohort of transfusion-dependent β-thalassemia patients who remained on the same monotherapy over 10 years. Musallam KM, Barella S, Origa R, Ferrero GB, Lisi R, Pasanisi A, Longo F, Gianesin B, Forni GL, Webthal® project. Blood Cells Mol Dis; 2024 Jul 15; 107():102859. PubMed ID: 38820707 [Abstract] [Full Text] [Related]
15. Deferiprone (GPO-L-ONE(®) ) monotherapy reduces iron overload in transfusion-dependent thalassemias: 1-year results from a multicenter prospective, single arm, open label, dose escalating phase III pediatric study (GPO-L-ONE; A001) from Thailand. Viprakasit V, Nuchprayoon I, Chuansumrit A, Torcharus K, Pongtanakul B, Laothamatas J, Srichairatanakool S, Pooliam J, Supajitkasem S, Suriyaphol P, Tanphaichitr VS, Tuchinda S. Am J Hematol; 2013 Apr 15; 88(4):251-60. PubMed ID: 23460233 [Abstract] [Full Text] [Related]
19. Effect of deferasirox on iron overload in patients with transfusion-dependent haemoglobinopathies. Fragomeno C, Roccabruna E, D'Ascola DG. Blood Cells Mol Dis; 2015 Dec 15; 55(4):382-6. PubMed ID: 26460263 [Abstract] [Full Text] [Related]
20. Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia: the ESCALATOR study. Taher A, El-Beshlawy A, Elalfy MS, Al Zir K, Daar S, Habr D, Kriemler-Krahn U, Hmissi A, Al Jefri A. Eur J Haematol; 2009 Jun 15; 82(6):458-65. PubMed ID: 19187278 [Abstract] [Full Text] [Related] Page: [Next] [New Search]